The impact of BCLC recommendations on survival for patients with hepatocellular carcinoma
BCLC_2022 and CDM provide greater flexibility in clinical practice without adversely affecting patient survival. Access to curative treatments improves the outcomes of selected patients in all stages.
Authors
- Annalisa De Silvestri (ORCID: https://orcid.org/0000-0003-3128-8441)
- Eleonora Alimenti (ORCID: https://orcid.org/0000-0001-8733-0245)
- Giuseppe Cabibbo (ORCID: https://orcid.org/0000-0002-0946-3859)
- Angelo Sangiovanni (ORCID: https://orcid.org/0000-0002-9996-9385)
- Barbara Antonelli (ORCID: https://orcid.org/0000-0001-8435-1294)
- Mariangela Bruccoleri (ORCID: https://orcid.org/0000-0001-7400-4854)
- L. Canova
- L. Caccamo (ORCID: https://orcid.org/0000-0002-5292-1376)
- Massimo Alberto Iavarone (ORCID: https://orcid.org/0000-0003-3493-6504)
- Gianpaolo Carrafiello (ORCID: https://orcid.org/0000-0003-1448-2808)
- Pietro Lampertico (ORCID: https://orcid.org/0000-0002-1026-7476)
- Anna Maria Ierardi
Institutions
- University of Milan (IT)
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT)
- Ospedale Maggiore (IT)
- Department of Health (ES)
- Policlinico San Matteo Fondazione (IT)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
Publication Details
- Journal
- Hepatology Communications
- Published
- 2025-07-14
- DOI
- https://doi.org/10.1097/hc9.0000000000000750
- Citations
- 6
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 7.93